The FDA typically requires medications to demonstrate efficacy in at least two Phase 3 trials prior to approval for a new purpose. Naltrexone reduces dopamine release from alcohol, blocking some of the pleasurable effects of drinking. Importantly, it also reduces alcohol craving, likely through its effects on dopamine that is released in response to cues, […]
Monthly Archives: June 2020
Archives
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- February 2024
- December 2023
- September 2023
- August 2023
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- January 2023
- December 2022
- November 2022
- October 2022
- August 2022
- July 2022
- June 2022
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- January 2021
- December 2020
- August 2020
- June 2020
- May 2019
Recent Comments